FDA Panel Snubs JNJ, CHMP Seeks More Data From PBYI, TBPH On Watch, AGRX Slumps

Today's Daily Dose brings you news about Agile's stock offering; FDA panel's thumbs down for arthritis drug Sirukumab; Theravence's mixed results from its phase IIb study of gastroparesis drug Velusetrag and setback for Puma's Neratinib in the E.U.

from RTT - Biotech http://ift.tt/2vv6YFp
via IFTTT